Meghan Fitzgerald
CIK 1349297 · EVP, Strategy & Health Policy · last filed 2026-09-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
THC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NAPLES, FL 34105
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ROIV | Director | 41,162 | $39.24 | $1.62M | -$3.27M | 13 | 2026-09-18 |
| THC | Director | 17,087 | $264.19 | $4.51M | -$3.68M | 15 | 2026-05-28 |
| Roivant Sciences Ltd. (ROIVW) Delisted | Director | 1,152 | $2.75 | $3.2K | $0 | 2 | 2023-07-06 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Director | — | $8.37 | — | $0 | 3 | 2018-06-18 |
| CAH | EVP, Strategy & Health Policy | 16,760 | $273.06 | $4.58M | $0 | 3 | 2015-11-17 |
| VION PHARMACEUTICALS INC (VION) Delisted | VP and Chief Business Officer | 55,500 | — | — | $0 | 1 | 2007-03-14 |
Recent Filings · Page 5 of 5
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-08-06 | CAH | Grant (A) | +7,818 | $0 | EDGAR |
| 2007-03-14 | VION PHARMACEUTICALS INC (VION) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).